stockportfolio.pro
Stocks / NGNE vs STRO
NGNE vs STRO
Neurogene Inc. and Sutro Biopharma, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Neurogene Inc. (NGNE) | Sutro Biopharma, Inc. (STRO) | |
|---|---|---|
| Market cap | $0.5B | $0.4B |
| Revenue (latest FY) | $0 | $102.48M |
| Net income (latest FY) | $-90.35M | $-191.09M |
| Revenue growth (5y CAGR) | — | 19.1% |
| Net margin | — | -186.5% |
| Return on equity | -34.1% | 144.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NGNE — free Open STRO — freeFrequently asked questions
Which is bigger, NGNE or STRO?
Neurogene Inc. is larger by market capitalization — $0.5B versus $0.4B.
Which grows faster, NGNE or STRO?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.